Clinical Trials Logo

Clinical Trial Summary

To integrate CARD in community pharmacy-led vaccinations and document impact on vaccine clients and pharmacy staff.


Clinical Trial Description

It is estimated that 1 out of 5 children and adults are not vaccinated because of concerns about pain and fear. The CARD (Comfort Ask Relax Distract) system is a new vaccine delivery system proven to reduce pain, fear and immunization stress-related responses. Improving the vaccination experiences of patients can improve attitudes about vaccination and increase vaccine acceptance. The objective of this cluster randomized trial is to evaluate scaling of CARD across community pharmacies on patients vaccination symptoms, beliefs and attitudes and pharmacy staff beliefs and attitudes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06098703
Study type Interventional
Source University of Toronto
Contact Charlotte Logeman, MPH
Phone 416-978-2889
Email charlotte.logeman@utoronto.ca
Status Not yet recruiting
Phase N/A
Start date November 1, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04109833 - Early Antibiotic Therapy and Vaccination
Completed NCT05043168 - Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination
Recruiting NCT05563753 - Early Antibiotic Therapy and Vaccinations in Preterm Infants
Completed NCT05160766 - Assessing Immune Response of Different COVID-19 Vaccines in Older Adults Phase 2
Recruiting NCT06023056 - Hepatitis B Vaccination After Neonatal Surgery
Withdrawn NCT05672654 - Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients N/A
Not yet recruiting NCT06373510 - Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study N/A
Completed NCT04934215 - Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
Recruiting NCT06294262 - Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine Phase 1/Phase 2